Literature DB >> 12039519

HLA expression in uveal melanoma: there is no rule without some exception.

Martine J Jager1, H Monique H Hurks, Jelena Levitskaya, Rolf Kiessling.   

Abstract

A decrease in the expression of HLA antigens is considered a characteristic of tumor progression and is considered an important tumor-escape mechanism. In general, HLA Class I expression is even further decreased on metastases. Tumor cells that loose their HLA Class I antigens become less susceptible to lysis by specific T cells, but may become more sensitive to Natural Killer cells. Loss of HLA Class I can be observed at different levels, i.e. total loss of Class I, loss of expression of one locus or one haplotype, or even one specific allele. We studied HLA expression on human uveal melanoma and observed that loss of expression of a locus or one or more alleles is a common phenomenon. However, in contrast with the commonly accepted paradigm, loss of HLA Class I expression on the uveal melanoma was not associated with tumor cell escape and a worse survival, but with a better survival of the patients involved. We hypothesize that this is due to the route of metastases formation: in uveal melanoma, spreading of metastases is purely hematogeneous, and it is quite possible that NK-cell mediated surveillance of tumor cells in the blood is the underlying mechanism. This is supported by our finding that metastases of uveal melanoma have a high HLA Class I expression, leading to our conclusion that uveal melanoma is an exception to the general rule regarding HLA Class I expression in tumor immunology.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12039519     DOI: 10.1016/s0198-8859(02)00389-0

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  37 in total

Review 1.  The Zimmerman-McLean-Foster hypothesis: 25 years later.

Authors:  A D Singh; I G Rennie; T Kivela; S Seregard; H Grossniklaus
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

2.  Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.

Authors:  Sudha Neelam; Jessamee Mellon; Amber Wilkerson; Jerry Y Niederkorn
Journal:  Melanoma Res       Date:  2019-08       Impact factor: 3.599

3.  Mechanisms of malignant glioma immune resistance and sources of immunosuppression.

Authors:  German G Gomez; Carol A Kruse
Journal:  Gene Ther Mol Biol       Date:  2006

Review 4.  Ocular diseases: immunological and molecular mechanisms.

Authors:  Jing Song; Yi-Fei Huang; Wen-Jing Zhang; Xiao-Fei Chen; Yu-Mian Guo
Journal:  Int J Ophthalmol       Date:  2016-05-18       Impact factor: 1.779

Review 5.  Immune escape mechanisms of intraocular tumors.

Authors:  Jerry Y Niederkorn
Journal:  Prog Retin Eye Res       Date:  2009-06-27       Impact factor: 21.198

Review 6.  Uveal melanoma as a target for immune-therapy.

Authors:  Marc Oliva; Antonio J Rullan; Josep M Piulats
Journal:  Ann Transl Med       Date:  2016-05

7.  Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.

Authors:  Fang Hou; Qi-Ming Huang; Dan-Ning Hu; Jost B Jonas; Wen-Bin Wei
Journal:  Int J Ophthalmol       Date:  2016-12-18       Impact factor: 1.779

8.  Reduced expression of autotaxin predicts survival in uveal melanoma.

Authors:  Arun D Singh; Karen Sisley; Yaomin Xu; Jianbo Li; Pieter Faber; Sarah J Plummer; Hardeep S Mudhar; Ian G Rennie; Patricia M Kessler; Graham Casey; Bryan G Williams
Journal:  Br J Ophthalmol       Date:  2007-05-02       Impact factor: 4.638

Review 9.  [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].

Authors:  M Kloor
Journal:  Pathologe       Date:  2013-11       Impact factor: 1.011

10.  Transporter associated protein expression in uveal melanoma.

Authors:  S Krishnakumar; S A Lakshmi; D Abhyankar; J Biswas
Journal:  Br J Ophthalmol       Date:  2004-07       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.